Daniel Copell Watson
First SEC filing: May 10, 2021 · Latest: May 10, 2021
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| April 9, 2024 | SKIN | A | 243,506 | · | · | 808,620 Direct | +43.09% | Acquired | (price as of 2026-10-02) |
| April 5, 2024 | SKIN | F | 11,212 | $3.71 | $41,597 | 778,112 Direct | -1.42% | Disposed | -83.0% (price as of 2026-10-02) |
| March 1, 2024 | SKIN | F | 6,356 | $3.73 | $23,708 | 789,324 Direct | -0.80% | Disposed | -83.1% (price as of 2026-10-02) |
| Feb. 4, 2024 | SKIN | F | 10,633 | $2.98 | $31,686 | 795,680 Direct | -1.32% | Disposed | -78.9% (price as of 2026-10-02) |
| Nov. 29, 2023 | SKIN | A | 156,250 | · | · | 565,114 Direct | +38.22% | Acquired | (price as of 2026-10-02) |
| April 5, 2023 | SKIN | A | 94,265 | · | · | 408,864 Direct | +29.96% | Acquired | (price as of 2026-10-02) |
| March 1, 2023 | SKIN | A | 17,560 | · | · | 314,599 Direct | +5.91% | Acquired | (price as of 2026-10-02) |
| Feb. 4, 2023 | SKIN | F | 8,972 | $12.90 | $115,739 | 806,313 Direct | -1.10% | Disposed | -95.1% (price as of 2026-10-02) |
| April 28, 2022 | SKIN | A | 187,500 | · | · | 187,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 4, 2022 | SKIN | A | 77,835 | · | · | 295,196 Direct | +35.81% | Acquired | (price as of 2026-10-02) |
| Aug. 25, 2021 | SKIN | J | 363 | · | · | 217,361 Direct | +0.17% | Acquired | (price as of 2026-10-02) |
| July 15, 2021 | SKIN | J | 38,429 | · | · | 216,998 Direct | +21.52% | Acquired | (price as of 2026-10-02) |
| May 20, 2021 | SKIN | J | 178,569 | · | · | 178,569 Direct | · | Acquired | (price as of 2026-10-02) |
| May 6, 2021 | SKIN | A | 310,000 | · | · | 310,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| April 28, 2022 | SKIN | Performance Restricted Stock Units | Class A Common Stock | · | · | 187,500 | Acquired |
| May 6, 2021 | SKIN | Stock Options (right to buy) [F1] | Common Stock | $12.85 | May 6, 2031 | 310,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $447,923 | $88,200 | $1,460,220 | · | $22,268 | · | $587,311 | $2,625,141 |
| 2023 | $419,231 | · | $2,444,749 | · | $112,014 | · | $14,309 | $3,011,271 |
| 2022 | $394,350 | $371,197 | $2,969,643 | · | · | · | $11,812 | $3,747,001 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.